{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06408259",
            "orgStudyIdInfo": {
                "id": "IM047-050"
            },
            "secondaryIdInfos": [
                {
                    "id": "2022-501332-42",
                    "type": "REGISTRY",
                    "domain": "EU Trial Number"
                },
                {
                    "id": "U1111-1281-5433",
                    "type": "REGISTRY",
                    "domain": "UTN"
                }
            ],
            "organization": {
                "fullName": "Celgene",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis",
            "officialTitle": "A Phase 3, Multicenter, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis",
            "therapeuticArea": [
                "Other"
            ],
            "study": "study-to-evaluate-the-effectiveness-and-safety-of-ozanimod-compared-to-fingolimod-in-children-and-adolescents-with-relapsing-remitting-multiple-sclerosis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-09",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2031-04-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2036-07-13",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-04-25",
            "studyFirstSubmitQcDate": "2024-05-06",
            "studyFirstPostDateStruct": {
                "date": "2024-05-10",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-06",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-10",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Celgene",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS)."
        },
        "conditionsModule": {
            "conditions": [
                "Multiple Sclerosis, Relapsing-Remitting"
            ],
            "keywords": [
                "Multiple Sclerosis",
                "Relapsing-Remitting",
                "Ozanimod",
                "Zeposia\u00ae"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 194,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Ozanimod",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Ozanimod",
                        "Other: Placebo"
                    ]
                },
                {
                    "label": "Fingolimod",
                    "type": "ACTIVE_COMPARATOR",
                    "interventionNames": [
                        "Drug: Fingolimod",
                        "Other: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Ozanimod",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Ozanimod"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fingolimod",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Fingolimod"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Fingolimod",
                        "Ozanimod"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Annualized relapse rate (ARR)",
                    "timeFrame": "Up to 2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Proportion of participants who did not have a confirmed relapse",
                    "timeFrame": "At 12 and 24 months"
                },
                {
                    "measure": "Number of gadolinium enhancing (GdE) T1 lesions",
                    "timeFrame": "At month 6 and month 12"
                },
                {
                    "measure": "Number of new or newly enlarging hyperintense lesions on T2 magnetic resonance imaging (MRI) sequences",
                    "timeFrame": "At 6, 12, 18, and 24 months"
                },
                {
                    "measure": "Incidence of treatment-emergent adverse events (TEAEs) over the treatment period and over the post-treatment follow-up period",
                    "timeFrame": "Up to 87 months"
                },
                {
                    "measure": "Incidence of adverse event of special interests (AESIs) over the treatment period and over the post-treatment follow-up period",
                    "timeFrame": "Up to 87 months"
                },
                {
                    "measure": "Adverse events (AEs) leading to discontinuation over the treatment period and over the post-treatment follow-up period",
                    "timeFrame": "Up to 87 months"
                },
                {
                    "measure": "Steady state plasma concentrations of ozanimod",
                    "timeFrame": "At day 90"
                },
                {
                    "measure": "Steady state plasma concentrations of the primary active metabolite CC112273",
                    "timeFrame": "At day 90"
                },
                {
                    "measure": "Change from baseline pharmacodynamics (PD) biomarkers of absolute lymphocyte count",
                    "timeFrame": "At day 90 and throughout the study up to 24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Has a diagnosis of multiple sclerosis (MS) as defined by the 2017 revision of the McDonald Criteria with a relapsing remitting course of disease.\n* Meets at least 1 of the following criteria for disease activity:\n\n  i) At least 1 MS relapse/attack in the previous year prior to screening.\n\nii) At least 2 MS relapses/attacks in the previous 2 years prior to screening.\n\niii) Evidence of 1 or more gadolinium-enhancing (GdE) lesions on magnetic resonance imaging (MRI) within 6 months prior to baseline (including screening MRI).\n\n- Has an Expanded Disability Status Scale (EDSS) score of 0 to 5.5, both inclusive.\n\nExclusion Criteria:\n\n* Diagnosis of progressive forms of MS.\n* Active or chronic disease of the immune system other than MS.\n* Clinically relevant cardiovascular, hepatic, neurological other major systematic disease.\n* Other protocol-defined Inclusion/Exclusion criteria apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "10 Years",
            "maximumAge": "17 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "BMS Study Connect Contact Center www.BMSStudyConnect.com",
                    "role": "CONTACT",
                    "phone": "855-907-3286",
                    "email": "Clinical.Trials@bms.com"
                },
                {
                    "name": "First line of the email MUST contain NCT # and Site #.",
                    "role": "CONTACT"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Bristol-Myers Squibb",
                    "affiliation": "Bristol-Myers Squibb",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "UCSF Benioff Children's Hospital San Francisco",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94158",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Emmanuelle Waubant, Site 0075",
                            "role": "CONTACT",
                            "phone": "415-514-2468"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Axiom Clinical Research of Florida",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33609",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mark Cascione, Site 0024",
                            "role": "CONTACT",
                            "phone": "813-353-9613"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "University of South Florida",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Derrick Robertson, Site 0053",
                            "role": "CONTACT",
                            "phone": "813-974-6378"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "Washington University",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Soe Mar, Site 0025",
                            "role": "CONTACT",
                            "phone": "314-732-0429"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Medical College of Wisconsin",
                    "city": "Milwaukee",
                    "state": "Wisconsin",
                    "zip": "53226",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ahmed Obeidat, Site 0033",
                            "role": "CONTACT",
                            "phone": "937-608-2712"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.0389,
                        "lon": -87.90647
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "BMS Clinical Trial Information",
                    "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"
                },
                {
                    "label": "BMS Clinical Trial Patient Recruiting",
                    "url": "https://www.bmsstudyconnect.com/s/US/English/USenHome"
                },
                {
                    "label": "Investigator Inquiry Form",
                    "url": "https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html"
                },
                {
                    "label": "FDA Safety Alerts and Recalls",
                    "url": "https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria.\n\nAdditional information regarding Bristol Myer Squibb's data sharing policy and process can be found at:\n\nhttps://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "CSR"
            ],
            "timeFrame": "See Plan Description",
            "accessCriteria": "See Plan Description",
            "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009103",
                    "term": "Multiple Sclerosis"
                },
                {
                    "id": "D000020529",
                    "term": "Multiple Sclerosis, Relapsing-Remitting"
                },
                {
                    "id": "D000012598",
                    "term": "Sclerosis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000020278",
                    "term": "Demyelinating Autoimmune Diseases, CNS"
                },
                {
                    "id": "D000020274",
                    "term": "Autoimmune Diseases of the Nervous System"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000003711",
                    "term": "Demyelinating Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12060",
                    "name": "Multiple Sclerosis",
                    "asFound": "Multiple Sclerosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M22314",
                    "name": "Multiple Sclerosis, Relapsing-Remitting",
                    "asFound": "Multiple Sclerosis, Relapsing-Remitting",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15415",
                    "name": "Sclerosis",
                    "asFound": "Sclerosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22098",
                    "name": "Demyelinating Autoimmune Diseases, CNS",
                    "relevance": "LOW"
                },
                {
                    "id": "M22094",
                    "name": "Autoimmune Diseases of the Nervous System",
                    "relevance": "LOW"
                },
                {
                    "id": "M6909",
                    "name": "Demyelinating Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000068876",
                    "term": "Fingolimod Hydrochloride"
                },
                {
                    "id": "C000607776",
                    "term": "Ozanimod"
                }
            ],
            "ancestors": [
                {
                    "id": "D000081243",
                    "term": "Sphingosine 1 Phosphate Receptor Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M216548",
                    "name": "Ozanimod",
                    "asFound": "Movement Disorders",
                    "relevance": "HIGH"
                },
                {
                    "id": "M323",
                    "name": "Fingolimod Hydrochloride",
                    "asFound": "Restorative",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}